SCHEMBL24464699

SCHEMBL24464699

C=C(/C=C/CN(C)C)NC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.37
ACKR3 P25106 1/20 0.36
EGFR P00533 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21787515 0.77 EGFR (0.32) EGFR
SCHEMBL23997975 0.77 KDM4E (0.36) KDM4E
SCHEMBL22330419 0.77 EGFR (0.32) EGFR
SCHEMBL9005243 0.76 EGFR (0.41) KDM4EACKR3EGFR
SCHEMBL21914141 0.74 KDM4E (0.33) KDM4E
SCHEMBL20322792 0.73 KDM4E (0.34) KDM4EEGFR
SCHEMBL26074486 0.69 CYP2D6 (0.33) KDM4E
SCHEMBL16610028 0.69
SCHEMBL14138758 0.69
SCHEMBL19954662 0.69 MEN1 (0.33) EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4006035-A1 QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER Neupharma, Inc. (US) 2022-06-01 EP disclosed